Current Issues in Molecular Biology (Apr 2024)

Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive Therapy of Autoimmune Diseases

  • Jonny,
  • Enda Cindylosa Sitepu,
  • Chairul A. Nidom,
  • Soetojo Wirjopranoto,
  • I. Ketut Sudiana,
  • Arif N. M. Ansori,
  • Terawan Agus Putranto

DOI
https://doi.org/10.3390/cimb46050249
Journal volume & issue
Vol. 46, no. 5
pp. 4035 – 4048

Abstract

Read online

Current therapies for autoimmune diseases are immunosuppressant agents, which have many debilitating side effects. However, dendritic cells (DCs) can induce antigen-specific tolerance. Tolerance restoration mediated by ex vivo-generated DCs can be a therapeutic approach. Therefore, in this review, we summarize the conceptual framework for developing ex vivo-generated DC strategies for autoimmune diseases. First, we will discuss the role of DCs in developing immune tolerance as a foundation for developing dendritic cell-based immunotherapy for autoimmune diseases. Then, we also discuss relevant findings from pre-clinical and clinical studies of ex vivo-generated DCs for therapy of autoimmune diseases. Finally, we discuss problems and challenges in dendritic cell therapy in autoimmune diseases. Throughout the article, we discuss autoimmune diseases, emphasizing SLE.

Keywords